Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.53 |
| ▸ | PDE4A | P27815 | 9/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905013 | 0.97 | PDE4D (0.57) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL1409590 | 0.84 | PDE4D (0.53) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL2593591 | 0.83 | RAB9A (0.55) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL1749072 | 0.83 | HTT (0.49) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL24214036 | 0.82 | RAB9A (0.54) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL31535540 | 0.81 | KMT2A (0.56) | PDE4DPDE4APDE4BPDE4CPARP10 | |
| SCHEMBL1750287 | 0.81 | MAPK1 (0.47) | LMNAMAPK1HTTRAB9APDE4D | |
| SCHEMBL15904302 | 0.81 | PDE4D (0.55) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13699100 | 0.80 | OPRK1 (0.57) | LMNAMAPK1HTTRAB9AHRH3 | |
| SCHEMBL1749280 | 0.80 | LMNA (0.52) | LMNAMAPK1HTTRAB9APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | LMNA 2677/4885MAPK1 496/4885HTT 1929/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | LMNA 2573/4885MAPK1 745/4885HTT 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.